The Charcot-Marie-Tooth Disease Type I A drugs in development market research report provides comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease Type I A, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Charcot-Marie-Tooth Disease Type I A. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Charcot-Marie-Tooth Disease Type I A and features dormant and discontinued products.
GlobalData tracks 21 drugs in development for Charcot-Marie-Tooth Disease Type I A by 21 companies/universities/institutes. The top development phase for Charcot-Marie-Tooth Disease Type I A is preclinical with 12 drugs in that stage. The Charcot-Marie-Tooth Disease Type I A pipeline has 19 drugs in development by companies and two by universities/ institutes. Some of the companies in the Charcot-Marie-Tooth Disease Type I A pipeline products market are: Armatus Bio, Oryzon Genomics and Sanofi.
The key targets in the Charcot-Marie-Tooth Disease Type I A pipeline products market include Peripheral Myelin Protein 22 (Growth Arrest Specific Protein 3 or GAS3 or PMP22), Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98), and Gamma-Aminobutyric Acid Type B Receptor Subunit (Gamma Aminobutyric Acid (GABA) B Receptor or GABBR).
The key mechanisms of action in the Charcot-Marie-Tooth Disease Type I A pipeline product include Peripheral Myelin Protein 22 (Growth Arrest Specific Protein 3 or GAS3 or PMP22) Inhibitor with nine drugs in Preclinical. The Charcot-Marie-Tooth Disease Type I A pipeline products include four routes of administration with the top ROA being Oral and six key molecule types in the Charcot-Marie-Tooth Disease Type I A pipeline products market including Small Molecule, and Gene Therapy.
Charcot-Marie-Tooth Disease Type I A overview
Charcot–Marie–Tooth disease type 1A (CMT1A), the most frequent form of CMT, is caused by a 1.5 Mb duplication on the short arm of chromosome 17. CMT1 is characterized by muscle weakness and atrophy, which can lead to repeated ankle sprains, and changes in sensation (paresthesia), which can cause clumsiness. Symptoms of this form of CMT usually start in childhood and mostly affect the periphery of the body, particularly in the feet, lower part of the legs, hands, and forearms.
For a complete picture of Charcot-Marie-Tooth Disease Type I A’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
